| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
68 |
| Employees |
156 |
| Revenues (TTM) (Millions $) |
35 |
| Net Income (TTM) (Millions $) |
-40 |
| Cash Flow (TTM) (Millions $) |
4 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Strongbridge Biopharma plc is a biopharmaceutical company that specializes in the development and commercialization of therapies for rare diseases. The company was founded in 1996 and is headquartered in Dublin, Ireland, with offices in the United States and Sweden.
Strongbridge Biopharma plc focuses on the development of products that address significant unmet medical needs in rare diseases, including endocrine disorders and rare neuromuscular diseases. The company's portfolio includes three commercial products, which are Keveyis, Macrilen, and Recorlev.
Keveyis is an FDA-approved oral medication used to treat people with primary periodic paralysis, a rare genetic disorder characterized by sudden episodes of muscle weakness or paralysis. Macrilen is another FDA-approved medication that is used for the diagnosis of patients with adult growth hormone deficiency. Recorlev is an investigative medication that is intended to treat endogenous Cushing's syndrome and is currently undergoing phase III clinical trials.
Strongbridge Biopharma plc has a skilled and experienced team of professionals who specialize in the research, development, and commercialization of innovative medicines. The company's research and development efforts are focused on creating products that offer significant advantages over existing therapies, which can lead to improved patient outcomes and lower healthcare costs.
The company has a strong financial position. In addition, Strongbridge Biopharma plc has a strong network of global partners and collaborators, which allows it to leverage the expertise of other organizations to develop and commercialize new therapies for rare diseases.
Overall, Strongbridge Biopharma plc is a leading biopharmaceutical company with a strong focus on developing innovative treatments for rare diseases. With a strong financial position and a highly skilled team of professionals, the company is well-positioned to continue to deliver innovative solutions that improve the lives of patients with rare diseases.
Company Address: 900 Northbrook Drive Trevose 19053 PA
Company Phone Number: 254-9200 Stock Exchange / Ticker: NASDAQ SBBP
|
%